Howard Stern, M.D., Ph.D., chief scientific officer of Korro Bio, is a seasoned biotechnology executive with over 15 years of experience in drug discovery and development ranging from preclinical research to correlative translational studies in the clinic. Howard has a passion for advancing novel therapeutic modalities to help patients with significant unmet medical need.
Most recently, Howard was the Chief Scientific Officer at FogPharma, a preclinical stage new modality company, where he drove the science that supported a recent series C financing round. Prior to his role at FogPharma, Howard was VP of Translational Sciences at Juno Therapeutics where he oversaw the pharmacology and correlative biomarker studies for engineered cellular therapies including lisocabtagene maraleucel (Breyanzi®).
Howard began his career as a scientist at Genentech where he conducted preclinical and translational research on mechanisms of drug resistance for numerous antibody and small molecule programs and contributed to several IND filings. He then transitioned to a leadership position as Director of Translational Science at Infinity Pharmaceuticals, where he oversaw the translational programs for the dual PI3K-d and PI3K-g inhibitor duvelisib (Copiktra®) and the PI3K-g selective inhibitor eganelisib.
Howard earned a Ph.D. in Biochemistry and an M.D. from the University of Washington and a BA in Chemistry from Pomona College. As part of his post-doctoral training, Howard completed a residency in Anatomic Pathology at Brigham and Women’s Hospital.